RANKL/OPG in Breast Cancer — Extending Its Territory to BRCA Mutation Carriers

مواد مشابهة

• Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
  بواسطة: Zaman, Tasnim, وآخرون
  منشور في: (2019)
• Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers
  بواسطة: Rebbeck, Timothy R, وآخرون
  منشور في: (2008)
• Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
  بواسطة: Martin Widschwendter, وآخرون
  منشور في: (2015-10-01)
• Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
  بواسطة: Widschwendter, Martin, وآخرون
  منشور في: (2015)
• Is bilateral radiation an option for BRCA mutation carriers with unilateral breast cancer?
  بواسطة: Narod, Steven A.
  منشور في: (2019)